October 6, 2014 / 4:35 PM / 5 years ago

BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study

Oct 6 (Reuters) - Ab Science SA :

* Says the Data and Safety Monitoring Board (DSMB) recommends the continuation of the phase 3 study of masitinib in progressive forms of multiple sclerosis

* Results confirm there are no observed safety concerns with masitinib over a 2-year treatment period Source text: bit.ly/Z9zWWo Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below